FGFR2 and cholangiocarcinoma: Here, we describe a cohort of 7 patients with FGFR2-driven CCA that have been treated with the multikinase TKI lenvatinib as first line FGFR2 targeted therapy and one additional patient that was treated with lenvatinib after developing resistance to the treatment with the selective FGFR2 inhibitor pemigatinib.